PEPTIDES (175 Offers)
Product Information
Dragon PharmaCompound Details
Active Substance Bronchogen Lyophilized bioregulatory peptide (Khavinson, lung-targeted)
20 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Limited human data · short-acting
Detection Limited data · Up to several weeks
Primary Mechanism Proposed Bronchial Gene-Expression Modulation
Cellular / Regenerative Impact Low (limited human data)
Product Information
Dragon PharmaCompound Details
Active Substance Cardiogen (AEDR) Lyophilized bioregulatory tetrapeptide (Khavinson, cardiac-targeted)
20 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Limited human data · short-acting
Detection Limited data · Up to several weeks
Primary Mechanism Proposed Cardiac Gene-Expression Modulation
Cellular / Regenerative Impact Low (limited human data)
Product Information
Dragon PharmaCompound Details
Active Substance FOXO4-DRI Lyophilized senolytic peptide (D-retro-inverso FOXO4/p53 inhibitor)
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data
Primary Mechanism FOXO4–p53 Disruption / Senolytic Apoptosis
Senolytic / Cellular Impact Low (no human data)
Product Information
Dragon PharmaCompound Details
Active Substance GHK-Cu (Copper Peptide) Lyophilized copper-binding tripeptide (basic form)
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Limited human data · short-acting
Detection Limited data · Up to several weeks
Primary Mechanism Copper-Dependent Collagen & Tissue Remodeling
Tissue Repair / Healing High (preclinical)
Product Information
Dragon PharmaCompound Details
Active Substance PNC-27 Lyophilized experimental anti-cancer peptide (p53-derived / HDM-2 targeting)
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data · S0-prohibited (non-approved substance)
Primary Mechanism Membrane HDM-2 Binding / Pore Formation
Anti-Cancer / Cellular Impact No Human Data
Product Information
Dragon PharmaCompound Details
Active Substance Prostamax (KEDP) Lyophilized bioregulatory tetrapeptide (Lys-Glu-Asp-Pro)
20 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data · S0-prohibited (non-approved substance)
Primary Mechanism Proposed Prostate Gene-Expression Modulation
Cellular / Regenerative Impact Low (no human data)
Product Information
Dragon PharmaCompound Details
Active Substance P21 (P021) Lyophilized CNTF-derived neurotrophic peptide (Ac-DGGLAG-NH₂)
5 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data · Up to several weeks
Primary Mechanism CNTF-Derived Neurotrophic Signalling / BDNF Upregulation
Neuroprotective / Cognitive Impact Moderate (preclinical)
Product Information
Dragon PharmaCompound Details
Active Substance LL-37 Lyophilized human cathelicidin antimicrobial peptide
5 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Limited human data · short-acting
Detection Limited data · Up to several weeks
Primary Mechanism Membrane Disruption / Immunomodulation
Antimicrobial / Immune Impact Low
Product Information
Dragon PharmaCompound Details
Active Substance Vesugen (KED) Lyophilized bioregulatory tripeptide (Lys-Glu-Asp)
20 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data
Primary Mechanism Endothelial Gene-Expression Modulation
Cellular / Regenerative Impact Low
Product Information
Dragon PharmaCompound Details
Active Substance Vilon (Lys-Glu) Lyophilized bioregulatory dipeptide (Lys-Glu)
20 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data
Primary Mechanism Thymic Gene-Expression Modulation
Cellular / Regenerative Impact Low
Product Information
Dragon PharmaCompound Details
Active Substance Vasoactive Intestinal Peptide (VIP) Lyophilized neuropeptide (28 aa)
6 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Approximately 1–2 Minutes (IV)
Detection Limited data
Primary Mechanism VPAC1/VPAC2 Receptor Agonism
Vasodilatory / Immunomodulatory Impact Moderate
Product Information
Dragon PharmaCompound Details
Active Substance ARA-290 (Cibinetide) Lyophilized EPO-derived innate repair receptor agonist (11 aa)
16 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data
Primary Mechanism Innate Repair Receptor (EPOR/CD131) Agonism
Tissue Repair / Neuroprotective Impact Moderate
Product Information
Dragon PharmaCompound Details
Active Substance Cartalax (AED) Lyophilized bioregulatory tripeptide (Ala-Glu-Asp)
20 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data
Primary Mechanism Connective-Tissue Gene-Expression Modulation
Cellular / Regenerative Impact Low
Product Information
Dragon PharmaCompound Details
Active Substance Melanotan I (Afamelanotide) Lyophilized synthetic α-MSH analogue (13 aa)
5 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life Approximately 30 Minutes
Detection Limited data
Primary Mechanism MC1R Agonism / Melanin Stimulation
Pigmentation / Tanning Effect High
Product Information
Dragon PharmaCompound Details
Active Substance Humanin Lyophilized mitochondrial-derived peptide (24 aa)
10 mg per vial
Form Lyophilized Powder
Packaging 2 mL Vial
Estimated Half-Life No published human PK data
Detection Limited data
Primary Mechanism gp130/WSX-1 Receptor Signalling / BAX Sequestration
Cytoprotective / Neuroprotective Impact Low
